Drug reference
metformin-sitagliptin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Endocrine (Peptide analogues)
Mechanism of action
Sitagliptin: Dipeptidyl peptidase 4 (DPP-4) inhibitor, thereby increasing and prolonging incretin hormone activity which are inactivated by DPP-4 enzyme. Metformin: Biguanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose.
Common side effects
- Vomiting
- Nausea
- Hypoglycemia
- Lactic acidosis
- Abdominal pain
- Diarrhea
Related conditions
Frequently asked questions
What drug class is metformin-sitagliptin?
metformin-sitagliptin belongs to: Endocrine.
How does metformin-sitagliptin work?
Sitagliptin: Dipeptidyl peptidase 4 (DPP-4) inhibitor, thereby increasing and prolonging incretin hormone activity which are inactivated by DPP-4 enzyme. Metformin: Biguanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose.
What are the common side effects of metformin-sitagliptin?
Vomiting, Nausea, Hypoglycemia, Lactic acidosis, Abdominal pain, Diarrhea
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.